Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
Charles S. Fuchs(University of Southern California), Harry H. Yoon(Mayo Clinic)
Cited by 1,802
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Long-Term Colorectal-Cancer Incidence and Mortality after Lower Endoscopy
|New England Journal of Medicine|2013|1.5k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Postmenopausal Hormone Therapy and Mortality
|New England Journal of Medicine|1997|1.2k